FTPSF
Fortis Inc.
No data for this timeframe.
Vol
SEC Reports2
Recent Activity
Apr 8, 2026
SEC
Fortis Inc. announced it will release its first quarter 2026 financial results on May 6, 2026, followed by a teleconfere
6-K — Impact 2/10
Mar 30, 2026
SEC
Fortis Inc. filed its 2026 management information circular, reporting strong 2025 financial performance with 5% adjusted
6-K — Impact 3/10
Analyst Ratings
2Strong Buy
7Buy
9Hold
2Sell
1Strong Sell
Latest Reports
NEUTRAL
6-K
2/10
Fortis Inc. announced it will release its first quarter 2026 financial results on May 6, 2026, followed by a teleconfere
Apr 8, 2026
NEUTRAL
6-K
3/10
Fortis Inc. filed its 2026 management information circular, reporting strong 2025 financial performance with 5% adjusted
Mar 30, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 43% buy across 21 analysts — 2 strong buy, 7 buy, 9 hold, 2 sell, 1 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 9 | 2 | 1 | 43% | |
| May 1, 2026 | 2 | 7 | 9 | 2 | 1 | 43% | |
| Apr 1, 2026 | 2 | 6 | 9 | 3 | 1 | 38% | |
| Mar 1, 2026 | 2 | 6 | 9 | 3 | 1 | 38% | |
| Feb 1, 2026 | 2 | 7 | 8 | 3 | 1 | 43% | |
| Jan 1, 2026 | 2 | 7 | 8 | 3 | 1 | 43% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.